Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors
- 1 January 2001
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 40 (12), 893-905
- https://doi.org/10.2165/00003088-200140120-00002
Abstract
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of compounds that induce allosteric changes in the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, thus rendering the enzyme incapable of converting viral RNA to DNA. Unlike nucleoside analogue inhibitors of reverse transcriptase, NNRTIs do not require sequential phosphorylation to elicit antiretroviral activity. There are currently 3 approved NNRTIs: nevirapine, delavirdine and efavirenz. Although possessing a common mechanism of action, these agents can be differentiated by both molecular and pharmacokinetic characteristics. Each of the NNRTIs is metabolised to some degree by the cytochrome P450 (CYP) system of enzymes, making them prone to clinically significant drug interactions. In addition, they elicit variable effects on other medications, acting as either inducers or inhibitors of drugs metabolised by CYP. These drug interactions are an important consideration in the clinical use of these agents as a part of combination antiretroviral therapy. Additional factors such as the influence of food and pH on oral absorption, and protein binding, must also be considered.Keywords
This publication has 40 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV-infected Children Participating in an Area-under-the-curve Controlled TrialClinical Pharmacology & Therapeutics, 2007
- Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected IndividualsClinical Pharmacokinetics, 2005
- Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1999
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV‐1 infected patientsBritish Journal of Clinical Pharmacology, 1999
- Cerebrospinal Fluid Human Immunodeficiency Virus Type 1 (HIV‐1) Suppression and Efavirenz Drug Concentrations in HIV‐1–Infected Patients Receiving Combination TherapyThe Journal of Infectious Diseases, 1999
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV InfectionClinical Pharmacokinetics, 1999
- Letter to the EditorsBritish Journal of Clinical Pharmacology, 1998
- Saquinavir Soft-Gel Capsule FormulationDrugs, 1998
- In vitro protein-binding characteristics of delavirdine and its N-dealkylated metaboliteAntiviral Research, 1996